Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
Authors:
Open Access
- 7 August 2020
- journal article
- research article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 35 (6) , 305-312
Abstract
This 7-day randomized, double-blind, placebo-controlled fixed-dose study (NCT03766867) explored the potential for accelerating the onset of antidepressant efficacy of single-dose intravenous (IV) vortioxetine at oral vortioxetine treatment initiation. Patients (ages 18–65 years) hospitalized per standard-of-care with major depressive disorder, who were currently treated with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor for a major depressive episode [Montgomery–Åsberg Depression Rating Scale (MADRS) total score ≥ 30], received one dose of single-blind IV placebo (1-day placebo lead-in period) before being randomly switched to either single-dose IV vortioxetine 25 mg plus daily oral vortioxetine 10 mg (n = 39), or IV placebo plus daily oral placebo (n = 41). In the placebo lead-in period, patients improved slightly by 0.6 MADRS-6 point; however, at day 1 after randomization, both treatment groups had improved by approximately 3 MADRS-6 points (mean difference = −0.8;P = 0.263), the study thus not meeting its primary endpoint. Similar results were seen for other outcomes except a numerically larger improvement in anxiety symptoms with vortioxetine vs placebo. Pharmacokinetic data confirmed that IV vortioxetine facilitated reaching steady-state plasma concentration within 24 h. IV plus oral vortioxetine was well tolerated, with low levels of nausea as the most common adverse event.Keywords
This publication has 31 references indexed in Scilit:
- Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trialEuropean Neuropsychopharmacology, 2012
- A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorderInternational Clinical Psychopharmacology, 2012
- The Clinical Pharmacokinetics of Lu AA21004 and its Major Metabolite in Healthy Young VolunteersBasic & Clinical Pharmacology & Toxicology, 2012
- Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptomsInternational Journal of Psychiatry in Clinical Practice, 2012
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInternational Journal of Neuropsychopharmacology, 2011
- The Serotonin-1A Receptor in Anxiety DisordersBiological Psychiatry, 2009
- Rapid Onset of Antidepressant ActionThe Journal of Clinical Psychiatry, 2008
- Assessing the clinical significance of change scores recorded on subjective outcome measuresJournal of Manipulative and Physiological Therapeutics, 2004
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979